Ipamorelin for Longevity and Anti-Aging: Protocol, Dosing, and What to Expect

What this protocol is for

Ipamorelin for longevity is a moderate use case anchored on its mechanism: restored GH pulse pattern toward the levels of a younger pituitary, without the cortisol and prolactin elevation that complicates older GHRPs. The case for longevity-specific outcomes (extended lifespan, reduced disease incidence) is mechanism-driven rather than trial-driven; the longevity clinical literature on Ipamorelin specifically is limited. What it does deliver functionally over 12 to 16 weeks: better sleep architecture, body composition trending toward leaner, faster recovery from training and minor illness, qualitative reports of feeling biologically younger.

The clinical pattern in user reports tracks the mechanism. Sleep effects show up first (typically weeks 1 to 2). Body composition and recovery effects follow over weeks 4 to 12. The cleaner side-effect profile compared to older GHRPs makes Ipamorelin the preferred GHRP for the long, slow, multi-cycle approach that longevity protocols require. Anecdotally, users running paired CJC + Ipamorelin cycles 2 to 3 times per year report cumulative improvements in functional age markers over 12 to 24 months.

Used by many in the recovery / biohacking space as part of a multi-pronged longevity stack. Run with a clinician who monitors IGF-1 and watches for any drift outside healthy range. This is a tactical, legal performance layer with caveats: the mechanism is real, the longevity-specific evidence is thinner, and the monitoring matters.

Dose for longevity and anti-aging

100 to 200 mcg subcutaneous per injection, 1 to 2 times daily. Lower dose than hypertrophy protocols because the goal is restoration toward a younger GH curve, not pharmacological elevation. Common rhythm: 100 to 200 mcg pre-sleep, optionally a second pre-training injection. Stack with CJC-1295 at the same dose per injection.

Cycle length

12 to 16 weeks on, 4 to 6 weeks off, 2 to 3 cycles per year. Longevity protocols favour the longer cycle because the cumulative benefit lands in months 3 to 4. Continuous use beyond 16 weeks degrades the signal.

Stack pairings

Commonly stacked with CJC-1295.

Expected timeline

Week 1–4: sleep improvements (deeper slow-wave, fewer mid-night wakings) show up first. Week 4–8: body composition shifts toward more lean tissue, less visceral fat. Week 8–16: cumulative functional gains in recovery, energy, and training capacity. Bloodwork IGF-1 elevation typically lands by week 4 and stays through the cycle.

Common mistakes

• Running Ipamorelin without bloodwork. For longevity-focused protocols, IGF-1 monitoring before, mid-cycle, and after matters. Upper-normal-for-age is the target; pharmacological elevation is not.
• Treating it as a continuous protocol without cycling. Pituitary adaptation degrades the signal. Cycling preserves responsiveness.
• Mixing with older GHRPs (GHRP-2, GHRP-6) for longevity. The clean profile of Ipamorelin is the reason it is the longevity-preferred GHRP. Stacking older GHRPs adds cortisol and prolactin elevation and loses the longevity-friendly cleanliness.
• Ignoring the cancer-risk conversation. Elevated IGF-1 has a complex relationship with cancer biology. This is a clinical conversation, particularly with family history.